Telomerase peptide vaccination in NSCLC: A phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial

Clinical Cancer Research

Volumn 17, Issue 21, 2011, Pages 6847-6857

  Brunsvig, Paal Fr ^a   Kyte, Jon Amund ^a   Kersten, Christian ^d   Sundstrum̀, Stein ^e   Mul̀ler, Mona ^b   Nyakas, Marta ^a   Hansen, Gaute L ^a   Gaudernack, Gustav ^a,c   Aamdal, Steinar ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b GemVax AS   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d Hospital of Southern Norway   (Norway)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TERTOMOTIDE; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ARTICLE; ASSAY; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CELLULAR IMMUNITY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; DELAYED HYPERSENSITIVITY; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EFFECTOR CELL; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INOPERABLE CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RELAPSE FREE SURVIVAL; SURVIVAL TIME; T LYMPHOCYTE; TH1 CELL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; PATIENT COMPLIANCE; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; TAXOIDS; TELOMERASE;

EID: 80455140226     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1385     Document Type: Article

References (47)

1. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009;15:4-9.
2. Cakir S, Egehan I. A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 2004;43:309-16. (Pubitemid 38224151)
3. Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small-cell lung cancer. J Clin Oncol 2005;23:3257-69. (Pubitemid 46211350)
4. Vokes EE, Crawford J, Bogart J, Socinski MA, Clamon G, Green MR. Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res 2005;11:5045-50.
5. Lam WK, Watkins DN. Lung cancer: future directions. Respirology 2007;12:471-7. (Pubitemid 46961832)
6. Brunsvig P, Aamdal S, Gjertsen MK, KvalheimG, Markowski-Grimsrud CJ, Sve I, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006;55:1553-64. (Pubitemid 44327843)
7. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
8. Fernandez-Garcia I, Ortiz-de-Solorzano C, Montuenga LM. Telomeres and telomerase in lung cancer. J Thorac Oncol 2008;3:1085-8.
9. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008;8:167-79. (Pubitemid 351305939)
10. Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005;174:3798-807. (Pubitemid 40354093)
11. Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 2004;10:4688-98. (Pubitemid 38955519)
12. Domchek SM, Recio A, Mick R, Clark CE, Carpenter EL, Fox KR, et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res 2007;67:10546-55. (Pubitemid 350070831)
13. Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 2007;25:2727-34. (Pubitemid 47123180)
14. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-9. (Pubitemid 29302920)
15. Szostak JW, Blackburn EH. Cloning yeast telomeres on linear plasmid vectors. Cell 1982;29:245-55. (Pubitemid 12027686)
16. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405-13. (Pubitemid 16213265)
17. Kyte JA. Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs 2009;18:687-94.
18. Shaw VE, Naisbitt DJ, Costello E, Greenhalf W, Park BK, Neoptolemos JP, et al. Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Rev Vaccines 2010;9:1007-16.
19. Greten TF, Forner A, Korangy F, N'Kontchou G, Barget N, Ayuso C, et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 2010;10:209.
20. Bernhardt SL, Gjertsen MK, Trachsel S, Moller M, Eriksen JA, Meo M, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006;95:1474-82. (Pubitemid 44863349)
21. Kyte JA, Trachsel S, Risberg B, thorStraten P, Lislerud K, Gaudernack G. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunol Immunother 2009;58:1609-26.
22. Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin Cancer Res 2011;17:4568-80.
23. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 2005;26:111-7.
24. Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, et al. A new era in anticancer peptide vaccines. Cancer 2010;116:2071-80.
25. Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as cancer treatment. Lancet 2009;373:673-83.
26. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8:59-73.
27. Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 2005;5:397-405.
28. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5. (Pubitemid 34303674)
29. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985-94. (Pubitemid 39446933)
30. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6. (Pubitemid 34441324)
31. Gonzalez-Aparicio M, Alzuguren P, Mauleon I, Medina-Echeverz J, Hervas-Stubbs S, Mancheno U, et al. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut 2010;60:341-9.
32. Huang X, Huang G, Song H, Chen L. Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced-killer cells in a murine lung carcinoma model. Int J Cancer 2010;129:648-58.
33. Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 2008;57:123-31. (Pubitemid 350043644)
34. Nowak AK, Lake RA, Robinson BW. Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev 2006;58:975-90. (Pubitemid 44780907)
35. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008;14:3536-44.
36. Kyte JA, Kvalheim G, Aamdal S, Saebùe-Larssen S, Gaudernack G. Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. Cancer Gene Ther 2005;12:579-91. (Pubitemid 40686598)
37. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001;92:441-50. (Pubitemid 32249724)
38. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54:721-8. (Pubitemid 40977140)
39. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12:878-87. (Pubitemid 43259871)
40. Bijker MS, Melief CJ, Offringa R, van der Burg SH. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 2007;6:591-603. (Pubitemid 47281301)
41. SpeetjensFM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 2009;15:1086-95.
42. Kyte JA, Kvalheim G, Lislerud K, Thor Straten P, Dueland S, Aamdal S, et al. T cell responses in melanoma patients after vaccination with tumor-mRNAtransfected dendritic cells. Cancer Immunol Immunother 2007;56:659-75. (Pubitemid 46348735)
43. Weden S, Klemp M, Gladhaug IP, Moller M, Eriksen JA, Gaudernack G, et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 2011;128:1120-8.
44. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4 +T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-42. (Pubitemid 27458961)
45. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 2008;105:20410-5.
46. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006;107:4781-9. (Pubitemid 43882629)
47. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007;13:843-50. (Pubitemid 47038186)